¼¼°èÀÇ ¾à¹°°¨½Ã ½ÃÀå
Pharmacovigilance
»óǰÄÚµå : 1588835
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2024³â 11¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 88 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,301,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,905,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¾à¹°°¨½Ã ¼¼°è ½ÃÀåÀº 2030³â±îÁö 185¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î Àü¸Á

2023³â 100¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°è ¾à¹°°¨½Ã ½ÃÀåÀº 2023³âºÎÅÍ 2030³â±îÁö ¿¬Æò±Õ 9.2% ¼ºÀåÇÏ¿© 2030³â¿¡´Â 185¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ °è¾àÇü ¾Æ¿ô¼Ò½ÌÀº CAGR 11.1%¸¦ ±â·ÏÇÏ¿© ºÐ¼® ±â°£ Á¾·á ½ÃÁ¡¿¡ 123¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÎÇϿ콺 ¼­ºñ½º Á¦°ø¾÷ü ºÎ¹®Àº ºÐ¼® ±â°£ µ¿¾È CAGR 6.1%ÀÇ ¼ºÀå·üÀ» ±â·ÏÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 26¾ï ´Þ·¯, Áß±¹Àº CAGR 12.7%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»ó

¹Ì±¹ÀÇ ¾à¹°°¨½Ã ½ÃÀåÀº 2023³â 26¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 43¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2023-2030³â ºÐ¼® ±â°£ µ¿¾È 12.7%ÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ´Ù¸¥ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ª ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ µ¿¾È °¢°¢ 5.7%¿Í 7.5%ÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ ¾à 6.9%ÀÇ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¼¼°è ¾à¹°°¨½Ã ½ÃÀå - ÁÖ¿ä µ¿Çâ ¹× ÃËÁø¿äÀÎ Á¤¸®

¾à¹°°¨½Ã¶õ ¹«¾ùÀ̸ç, ÇコÄɾ¼­ ¿Ö Áß¿äÇѰ¡?

¾à¹°°¨½Ã¶õ ºÎÀÛ¿ë ¹× ±âŸ ¾à¹° °ü·Ã ¹®Á¦¸¦ °¨Áö, Æò°¡, ÀÌÇØ ¹× ¿¹¹æÇÏ´Â °Í°ú °ü·ÃµÈ °úÇÐ ¹× Ȱµ¿À» ¸»ÇÕ´Ï´Ù. °³¹ßºÎÅÍ ½ÃÆÇ ÈÄ Á¶»ç±îÁö ÀǾàǰÀÇ Àüü ¼ö¸íÁֱ⠵¿¾È ¾ÈÀü¼º°ú À¯È¿¼ºÀ» º¸ÀåÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. ¾à¹°°¨½ÃÀÇ ÁÖ¿ä ¸ñÀûÀº ÀǾàǰ »ç¿ë°ú °ü·ÃµÈ À§ÇèÀ» ½Äº°ÇÏ°í ¿ÏÈ­ÇÏ¿© °øÁß º¸°ÇÀ» º¸È£ÇÏ´Â °ÍÀÔ´Ï´Ù. ÀǾàǰ¿¡´Â ÀÓ»ó½ÃÇè Áß¿¡ ÃæºÐÈ÷ ¹àÇôÁöÁö ¾Ê´Â ºÎÀÛ¿ëÀÌ Àֱ⠶§¹®¿¡ ¾à¹°°¨½Ã¸¦ ÅëÇØ ÀǾàǰÀÌ ³Î¸® »ç¿ëµÇ±â ½ÃÀÛÇÑ ÀÌÈÄ¿¡µµ ÀǾàǰÀÇ ¾ÈÀü¼ºÀ» Áö¼ÓÀûÀ¸·Î ¸ð´ÏÅ͸µÇÒ ¼ö ÀÖ´Â ¸ÞÄ¿´ÏÁòÀ» Á¦°øÇÕ´Ï´Ù.

¾à¹°°¨½Ã¿¡´Â ºÎÀÛ¿ë º¸°í(ADR) µ¥ÀÌÅÍ ¼öÁý ¹× ºÐ¼®, À§Ç輺 Æò°¡ ¼öÇà, ȯÀÚ ÇÇÇØ¸¦ ÁÙÀ̱â À§ÇÑ Á¶Ä¡ ½ÃÇà µî ´Ù¾çÇÑ È°µ¿ÀÌ Æ÷ÇԵ˴ϴÙ. ±ÔÁ¦ ´ç±¹, Á¦¾à»ç, ÀÇ·á Àü¹®°¡°¡ ¸ðµÎ ¾à¹°°¨½Ã¸¦ ÅëÇØ ÀǾàǰ°ú °ü·ÃµÈ ÀáÀçÀû ¾ÈÀü ¹®Á¦¸¦ ½Å¼ÓÇÏ°Ô ½Äº°Çϰí ÇØ°áÇÒ ¼ö ÀÖµµ·Ï ÇÕ´Ï´Ù. Á¦¾à ¾÷°è°¡ »ý¹°ÇÐÀû Á¦Á¦ ¹× ¸ÂÃãÇü Ä¡·áÁ¦¿Í °°ÀÌ ´õ¿í º¹ÀâÇÑ ½Å¾àÀ» °è¼Ó °³¹ßÇÔ¿¡ µû¶ó, ¾à¹°°¨½Ã°¡ ÀǾàǰÀÇ ¾ÈÀü¼ºÀ» À¯ÁöÇϰí ȯÀÚ¸¦ º¸È£ÇÏ´Â µ¥ ÀÖ¾î ´õ¿í Áß¿äÇØÁö°í ÀÖ½À´Ï´Ù.

±â¼úÀÇ ¹ßÀüÀº ¾î¶»°Ô ¾à¹°°¨½Ã ½ÃÀåÀ» Çü¼ºÇϰí Àִ°¡?

±â¼úÀÇ ¹ßÀüÀº ¾à¹°°¨½Ã ½ÃÀå¿¡¼­ Çõ½ÅÀûÀÎ ¿ªÇÒÀ» Çϰí ÀÖÀ¸¸ç, ¾à¹° ¾ÈÀü¼º ¸ð´ÏÅ͸µÀÇ È¿À²¼º°ú Á¤È®¼ºÀ» Çâ»ó½Ã۰í ÀáÀçÀû À§ÇèÀ» ½Äº°ÇÏ´Â ´É·ÂÀ» Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. ÀÌ ºÐ¾ßÀÇ °¡Àå Áß¿äÇÑ ¹ßÀü Áß Çϳª´Â ÀΰøÁö´É(AI)°ú ¸Ó½Å·¯´×(ML)À» ¾à¹°°¨½Ã ÇÁ·Î¼¼½º¿¡ ÅëÇÕÇÏ´Â °ÍÀ¸·Î, AI ¹× ML ¾Ë°í¸®ÁòÀº ȯÀÚ ±â·Ï, ¼Ò¼È ¹Ìµð¾î ¹ß¾ð, ÀüÀÚ ÀÇ·á ±â·Ï µî ´ë·®ÀÇ ½ÇÁ¦ µ¥ÀÌÅ͸¦ ºÐ¼®ÇÏ¿© ºÎÀÛ¿ë(ADR)À» ³ªÅ¸³¾ ¼ö ÀÖ´Â ÆÐÅÏÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù. ºÎÀÛ¿ë(ADR)À» ³ªÅ¸³¾ ¼ö ÀÖ´Â ÆÐÅÏÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀ» ÅëÇØ º¸´Ù Àû±ØÀûÀÎ ¸ð´ÏÅ͸µÀÌ °¡´ÉÇØÁ® ÀáÀçÀûÀÎ ¾ÈÀü ¹®Á¦°¡ È®»êµÇ±â Àü¿¡ Á¶±â¿¡ ¹ß°ßÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÚµ¿È­´Â ¾à¹°°¨½Ã ½ÃÀåÀ» Çü¼ºÇÏ´Â ¶Ç ´Ù¸¥ Áß¿äÇÑ Æ®·»µåÀÔ´Ï´Ù. ÀÚµ¿È­ ½Ã½ºÅÛÀº µ¥ÀÌÅÍ ¼öÁý, º¸°í¼­ ÀÛ¼º, ½ÅÈ£ °¨Áö µîÀÇ ÀÛ¾÷À» ±âÁ¸ ¼öÀÛ¾÷º¸´Ù ´õ ºü¸£°í Á¤È®ÇÏ°Ô Ã³¸®ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ·Îº¿ ÇÁ·Î¼¼½º ÀÚµ¿È­(RPA)´Â ADR º¸°í¼­ ¼öÁý ¹× ºÐ¼®À» °£¼ÒÈ­Çϰí, ÀÀ´ä ½Ã°£À» °³¼±Çϰí, ÀÎÀû ¿À·ù¸¦ ÁÙÀ̱â À§ÇØ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀÚ¿¬¾î ó¸®(NLP) ±â¼úÀº ÀÓ»ó ±â·Ï ¹× ȯÀÚ º¸°í¼­¿Í °°Àº ºñÁ¤Çü µ¥ÀÌÅÍ ¼Ò½º¿¡¼­ °ü·Ã ¾ÈÀü¼º Á¤º¸¸¦ ÃßÃâÇÏ´Â ´É·ÂÀ» Çâ»ó½ÃÄÑ ´Ù¸¥ ¹æ¹ýÀ¸·Î´Â ¹ß°ßµÇÁö ¾ÊÀ» ¼ö ÀÖ´Â ºÎÀÛ¿ëÀ» ½±°Ô ½Äº°ÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù.

¶ÇÇÑ, Ŭ¶ó¿ìµå ±â¹Ý ¾à¹°°¨½Ã Ç÷§ÆûÀÇ µîÀåÀ¸·Î Á¦¾à»ç, ±ÔÁ¦ ´ç±¹, ÀÇ·á ¼­ºñ½º Á¦°øÀÚ µî ÀÌÇØ°ü°èÀÚ °£ÀÇ Çù¾÷ÀÌ ´õ¿í Ȱ¹ßÇØÁö°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ç÷§ÆûÀº ADR µ¥ÀÌÅ͸¦ ½Ç½Ã°£À¸·Î ÀúÀå, °øÀ¯ ¹× ºÐ¼®ÇÒ ¼ö ÀÖ´Â Áß¾Ó ÁýÁᫎ µ¥ÀÌÅͺ£À̽º¸¦ Á¦°øÇÏ¿© º¸´Ù ½Å¼ÓÇÑ ÀÇ»ç°áÁ¤°ú È¿À²ÀûÀÎ º¸°í¸¦ °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. ¶ÇÇÑ, ºòµ¥ÀÌÅÍ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ¹æ´ëÇÑ ¾çÀÇ È¯ÀÚ µ¥ÀÌÅ͸¦ ºÐ¼®ÇÏ¿© ÀáÀçÀûÀÎ ¾ÈÀü¼º ¹®Á¦¸¦ ³ªÅ¸³¾ ¼ö ÀÖ´Â °æÇâ°ú »ó°ü°ü°è¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖ¾î ½ÃÆÇ ÈÄ Á¶»ç¿¡ Çõ¸íÀ» ÀÏÀ¸Å°°í ÀÖ½À´Ï´Ù.

¾à¹°°¨½ÃÀÇ »õ·Î¿î Æ®·»µå´Â ¹«¾ùÀϱî?

Á¦¾à ¾÷°è°¡ ÁøÈ­ÇÏ´Â µµÀü°ú ±âȸ¿¡ Á÷¸éÇϰí ÀÖ´Â °¡¿îµ¥, ¸î °¡Áö »õ·Î¿î Æ®·»µå°¡ ¾à¹°°¨½Ã ½ÃÀåÀ» ÀçÆíÇϰí ÀÖ½À´Ï´Ù. °¡Àå Áß¿äÇÑ Æ®·»µå Áß Çϳª´Â ÀǾàǰ ¾ÈÀü¼º ¸ð´ÏÅ͸µ¿¡¼­ ¸®¾ó¿ùµå¿¡ºñ´ø½º(RWE)¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö°í ÀÖ´Ù´Â Á¡ÀÔ´Ï´Ù. RWE´Â ƯÈ÷ ´Ù¾çÇÑ È¯ÀÚ Áý´Ü¿¡¼­ ÅëÁ¦µÈ ÀÓ»ó ȯ°æ°ú ´Ù¸£°Ô ÇൿÇÒ ¼ö ÀÖ´Â ÀǾàǰ¿¡ ´ëÇØ º¸´Ù Á¾ÇÕÀûÀÎ ¾ÈÀü¼º Æò°¡¸¦ °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. ±× °á°ú, Á¦¾àȸ»ç¿Í ±ÔÁ¦ ´ç±¹Àº RWE¸¦ ÀÚ»çÀÇ ¾à¹°°¨½Ã Àü·«¿¡ µµÀÔÇϰí ÀÖ½À´Ï´Ù.

¶Ç ´Ù¸¥ Áß¿äÇÑ Ãß¼¼´Â ¾à¹°°¨½ÃÀÇ ¼¼°èÈ­°¡ ÁøÇàµÇ°í ÀÖ´Ù´Â Á¡ÀÔ´Ï´Ù. Á¦¾à»çµéÀÌ ±¹Á¦ ½ÃÀåÀ¸·Î ÁøÃâÇÔ¿¡ µû¶ó °¢ Áö¿ªÀÇ ´Ù¾çÇÑ ±ÔÁ¦ ¿ä°ÇÀ» ÃæÁ·½ÃÄÑ¾ß ÇÕ´Ï´Ù. µû¶ó¼­ ¾ÈÀü¼º µ¥ÀÌÅͰ¡ ÇöÁö ±ÔÁ¤À» ÁؼöÇÏ¿© ¼öÁýµÇ°í º¸°íµÇ´Â °ÍÀ» º¸ÀåÇϸ鼭 Àü ¼¼°èÀûÀ¸·Î ¿î¿µÇÒ ¼ö ÀÖ´Â ¾à¹°°¨½Ã ¼­ºñ½º¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¹Ì±¹, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç µîÀÇ ±ÔÁ¦ ´ç±¹Àº ÀǾàǰ ¾ÈÀü¿¡ ´ëÇÑ ¾ö°ÝÇÑ °¡À̵å¶óÀÎÀ» Á¦Á¤Çϰí ÀÖÀ¸¸ç, Á¦¾àȸ»ç´Â ÀÌ·¯ÇÑ ±âÁØÀ» ÃæÁ·ÇÒ ¼ö ÀÖ´Â °ß°íÇÑ ¾à¹°°¨½Ã ½Ã½ºÅÛÀ» À¯ÁöÇØ¾ß ÇÕ´Ï´Ù.

¾à¹°°¨½Ã¿¡¼­µµ ¸®½ºÅ© °ü¸®¿Í »çÀü ¿¹¹æÀû ¾ÈÀü¼º ¸ð´ÏÅ͸µÀº Á¡Á¡ ´õ Áß¿äÇØÁö°í ÀÖ½À´Ï´Ù. ºÎÀÛ¿ëÀÌ ¹ß»ýÇÑ ÈÄ ´ëÀÀÇÏ´Â °ÍÀÌ ¾Æ´Ï¶ó ÀáÀçÀûÀÎ ¾ÈÀü¼º ¹®Á¦°¡ ¹ß»ýÇϱâ Àü¿¡ ¿¹¹æÇϱâ À§ÇØ À§Çè °ü¸® °èȹ(RMP)°ú À§Çè °¨¼Ò Àü·«À» äÅÃÇÏ´Â ±â¾÷ÀÌ ´Ã°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù¹ý¿¡´Â ½ÃÆÇ Àü À§Çè Æò°¡, ½ÃÆÇ ÈÄ Áö¼ÓÀûÀÎ ¸ð´ÏÅ͸µ, µ¥ÀÌÅÍ µ¿Çâ¿¡¼­ »õ·Î¿î À§ÇèÀ» ½Äº°ÇÏ´Â ½ÅÈ£ °¨Áö µµ±¸ÀÇ »ç¿ë µîÀÌ Æ÷ÇԵ˴ϴÙ. ¶ÇÇÑ, ȯÀÚ Á᫐ ¾à¹°°¨½Ã(patient-centric pharmacovigilance)ÀÇ ºÎ»óÀ¸·Î ȯÀÚµéÀÇ Á÷Á¢ÀûÀÎ ÀǰßÀÇ Á߿伺ÀÌ °­Á¶µÇ°í ÀÖÀ¸¸ç, ±â¾÷µéÀº ¼³¹® Á¶»ç, ¼Ò¼È ¹Ìµð¾î, ¸ð¹ÙÀÏ °Ç°­ ¾Û µîÀ» Ȱ¿ëÇÏ¿© ȯÀÚ°¡ º¸°íÇÑ °á°ú¿Í ¾à¹° »ç¿ë °æÇèÀ» ¼öÁýÇϰí ÀÖ½À´Ï´Ù.

¾à¹°°¨½Ã ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÏ´Â ¿äÀÎÀº ¹«¾ùÀϱî?

¾à¹°°¨½Ã ½ÃÀåÀÇ ¼ºÀåÀº ±ÔÁ¦ ´ç±¹ÀÇ °¨½Ã °­È­, ¾à¹° Ä¡·áÀÇ º¹À⼺ Áõ°¡, ±â¼ú Çõ½Å µî ¿©·¯ ¿äÀο¡ ÀÇÇØ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. ƯÈ÷ »ý¹°ÇÐÀû Á¦Á¦, À¯ÀüÀÚ Ä¡·á, ¸ÂÃã ÀÇ·á µîÀÇ ºÐ¾ß¿¡¼­ ½Å¾à ½ÂÀÎ °Ç¼ö°¡ Áõ°¡Çϰí ÀÖ´Â °ÍÀÌ ÁÖ¿ä ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù. ÀÌ·¯ÇÑ Ä¡·á¹ýÀº Á¾Á¾ º¹ÀâÇÑ ¾ÈÀü¼º ÇÁ·ÎÆÄÀÏÀ» ¼ö¹ÝÇÏ´Â °æ¿ì°¡ ¸¹À¸¸ç, º¸´Ù ÁýÁßÀûÀÎ ½ÃÆÇ ÈÄ ¸ð´ÏÅ͸µÀÌ ÇÊ¿äÇÕ´Ï´Ù. Á¦¾à»çµéÀÌ º¸´Ù Çõ½ÅÀûÀÌ°í °³ÀÎÈ­µÈ ÀǾàǰÀ» ½ÃÀå¿¡ Ãâ½ÃÇÔ¿¡ µû¶ó ȯÀÚ ¾ÈÀüÀ» º¸ÀåÇϱâ À§ÇÑ Á¾ÇÕÀûÀÎ ¾à¹°°¨½Ã ¼­ºñ½º¿¡ ´ëÇÑ ¼ö¿ä°¡ Å©°Ô Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

½ÃÀå ¼ºÀåÀ» ÃËÁøÇÏ´Â ¶Ç ´Ù¸¥ Áß¿äÇÑ ¿äÀÎÀº ÀǾàǰ ¾ÈÀü¿¡ ´ëÇÑ ±ÔÁ¦ ¿ä°ÇÀÌ °­È­µÇ°í ÀÖ´Ù´Â Á¡ÀÔ´Ï´Ù. ¹Ì±¹ FDA¿Í À¯·´ÀǾàǰû(EMA)°ú °°Àº ±ÔÁ¦ ±â°üÀº ¾ö°ÝÇÑ ¾à¹°°¨½Ã °¡À̵å¶óÀÎÀ» µµÀÔÇϰí ÀÖÀ¸¸ç, ÀǾàǰÀÌ ½ÃÆÇ Çã°¡¸¦ ¹ÞÀº ÈÄ¿¡µµ Áö¼ÓÀûÀÎ ¸ð´ÏÅ͸µÀ» ½Ç½ÃÇϵµ·Ï ¿ä±¸Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±ÔÁ¤À» ÁؼöÇÏÁö ¾ÊÀ» °æ¿ì, ¸·´ëÇÑ ¹ú±ÝÀÌ ºÎ°úµÇ°Å³ª Á¦Ç°ÀÌ È¸¼öµÇ°í ±â¾÷ÀÇ ÆòÆÇÀÌ ³ªºüÁú ¼ö ÀÖ½À´Ï´Ù. µû¶ó¼­ Á¦¾à»çµéÀº ±ÔÁ¤ Áؼö¸¦ º¸ÀåÇÏ°í ±ÔÁ¦ ¸®½ºÅ©¸¦ ÇÇÇϱâ À§ÇØ ¾à¹°°¨½Ã ½Ã½ºÅÛ¿¡ ¸¹Àº ÅõÀÚ¸¦ Çϰí ÀÖ½À´Ï´Ù.

±â¼úÀÇ ¹ßÀüµµ ¾à¹°°¨½Ã ½ÃÀåÀÇ ¼ºÀå¿¡ ±â¿©Çϰí ÀÖÀ¸¸ç, AI, ÀÚµ¿È­, ºòµ¥ÀÌÅÍ ºÐ¼®ÀÇ ÅëÇÕÀº ±â¾÷ÀÌ ÀǾàǰ ¾ÈÀü¼º ¸ð´ÏÅ͸µ¿¡ Á¢±ÙÇÏ´Â ¹æ½ÄÀ» Çõ½ÅÀûÀ¸·Î º¯È­½ÃÄÑ º¸´Ù È¿À²ÀûÀ̰í, È®Àå °¡´ÉÇϸç, ºñ¿ë È¿À²ÀûÀ¸·Î ¸¸µé°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀ» ÅëÇØ ±â¾÷Àº ¹æ´ëÇÑ ¾çÀÇ µ¥ÀÌÅ͸¦ ½Ç½Ã°£À¸·Î ºÐ¼®ÇÏ¿© ¾ÈÀü¼º Æò°¡ÀÇ ¼Óµµ¿Í Á¤È®¼ºÀ» Çâ»ó½Ãų ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¶ÇÇÑ, Ŭ¶ó¿ìµå ±â¹Ý ¼Ö·ç¼Ç°ú ¼¼°è ¾à¹°°¨½Ã ³×Æ®¿öÅ©ÀÇ ºÎ»óÀ¸·Î Á¦¾à ¾÷°è Àü¹ÝÀÇ Çù¾÷°ú µ¥ÀÌÅÍ °øÀ¯°¡ ÃËÁøµÇ°í ÀÖÀ¸¸ç, ÀÌ´Â ½ÃÀåÀÇ ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

¸¶Áö¸·À¸·Î, ȯÀÚ ¾ÈÀü°ú Åõ¸í¼º¿¡ ´ëÇÑ È¯ÀÚµéÀÇ °ü½ÉÀÌ ³ô¾ÆÁø °ÍÀÌ ÁÖ¿ä ÃËÁø¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ȯÀÚµéÀÌ ÀǾàǰ°ú °ü·ÃµÈ ÀáÀçÀû À§Çè¿¡ ´ëÇØ ´õ ¸¹Àº Á¤º¸¸¦ ¾ò°Ô µÊ¿¡ µû¶ó Á¦¾à»ç´Â ÀǾàǰÀÇ ¾ÈÀü¼ºÀ» º¸ÀåÇÏ°í ºÎÀÛ¿ëÀ» ½Å¼ÓÇϰí Åõ¸íÇÏ°Ô º¸°íÇØ¾ß ÇÑ´Ù´Â ¾Ð¹ÚÀ» ¹Þ°í ÀÖ½À´Ï´Ù. Ã¥ÀÓ°¨ °­È­¿Í ȯÀÚ Áß½ÉÀÇ Á¢±Ù ¹æ½ÄÀ¸·ÎÀÇ ÀüȯÀº ÀǾàǰÀÇ ¾ÈÀü¼ºÀ» ¸ð´ÏÅ͸µÇÏ°í ±ÔÁ¦ ´ç±¹°ú ÀÇ·á ¼­ºñ½º Á¦°øÀÚ¿¡°Ô Àû½Ã¿¡ ÃֽŠÁ¤º¸¸¦ Á¦°øÇÒ ¼ö ÀÖ´Â °­·ÂÇÑ ¾à¹°°¨½Ã ½Ã½ºÅÛ¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀº Çõ½ÅÀûÀÎ Ä¡·á¹ýÀÇ Áö¼ÓÀûÀÎ °³¹ß°ú ÇÔ²² ¾à¹°°¨½Ã ½ÃÀåÀÇ ¼ºÀåÀ» °ßÀÎÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê(ÃÑ 32°Ç)

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Pharmacovigilance Market to Reach US$18.5 Billion by 2030

The global market for Pharmacovigilance estimated at US$10.0 Billion in the year 2023, is expected to reach US$18.5 Billion by 2030, growing at a CAGR of 9.2% over the analysis period 2023-2030. Contract Outsourcing, one of the segments analyzed in the report, is expected to record a 11.1% CAGR and reach US$12.3 Billion by the end of the analysis period. Growth in the In-House Service Provider segment is estimated at 6.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.6 Billion While China is Forecast to Grow at 12.7% CAGR

The Pharmacovigilance market in the U.S. is estimated at US$2.6 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$4.3 Billion by the year 2030 trailing a CAGR of 12.7% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.7% and 7.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.9% CAGR.

Global Pharmacovigilance Market – Key Trends & Drivers Summarized

What Is Pharmacovigilance and Why Is It Important in Healthcare?

Pharmacovigilance refers to the science and activities related to the detection, assessment, understanding, and prevention of adverse effects or other drug-related problems. It plays a crucial role in ensuring the safety and efficacy of pharmaceutical products throughout their lifecycle, from development to post-market surveillance. The primary goal of pharmacovigilance is to protect public health by identifying and mitigating risks associated with the use of drugs. As pharmaceutical products can have side effects that are not fully apparent during clinical trials, pharmacovigilance provides an ongoing mechanism for monitoring the safety of drugs once they are in widespread use.

Pharmacovigilance encompasses various activities, such as collecting and analyzing data from adverse drug reaction (ADR) reports, conducting risk assessments, and implementing measures to reduce harm to patients. Regulatory authorities, pharmaceutical companies, and healthcare professionals are all involved in pharmacovigilance, ensuring that any potential safety concerns related to a drug are quickly identified and addressed. As the pharmaceutical industry continues to develop new and more complex drugs, including biologics and personalized therapies, pharmacovigilance has become even more critical in maintaining drug safety and protecting patients.

How Are Technological Advancements Shaping the Pharmacovigilance Market?

Technological advancements are playing a transformative role in the pharmacovigilance market, improving the efficiency and accuracy of drug safety monitoring and enhancing the ability to identify potential risks. One of the most significant advancements in this field is the integration of artificial intelligence (AI) and machine learning (ML) into pharmacovigilance processes. AI and ML algorithms are capable of analyzing large volumes of real-world data, such as patient records, social media mentions, and electronic health records, to identify patterns that may indicate adverse drug reactions (ADRs). These technologies allow for more proactive monitoring, enabling early detection of potential safety concerns before they become widespread.

Automation is another key trend shaping the pharmacovigilance market. Automated systems can handle tasks such as data collection, report generation, and signal detection with greater speed and accuracy than traditional manual methods. For instance, robotic process automation (RPA) is being used to streamline the collection and analysis of ADR reports, improving response times and reducing human error. In addition, natural language processing (NLP) technologies are enhancing the ability to extract relevant safety information from unstructured data sources, such as clinical notes and patient reports, making it easier to identify adverse reactions that might otherwise go unnoticed.

Furthermore, the rise of cloud-based pharmacovigilance platforms is enabling greater collaboration between stakeholders, including pharmaceutical companies, regulatory authorities, and healthcare providers. These platforms offer centralized databases where ADR data can be stored, shared, and analyzed in real-time, allowing for faster decision-making and more efficient reporting. Additionally, the adoption of big data analytics is revolutionizing post-market surveillance, as companies can now analyze vast amounts of patient data to identify trends and correlations that could indicate potential safety issues.

What Are the Emerging Trends in Pharmacovigilance?

Several emerging trends are reshaping the pharmacovigilance market as the pharmaceutical industry faces evolving challenges and opportunities. One of the most significant trends is the growing focus on real-world evidence (RWE) in drug safety monitoring. RWE is derived from data collected outside of clinical trials, such as patient records, insurance claims, and registries, providing a broader understanding of how drugs perform in real-world settings. The use of RWE allows for more comprehensive safety assessments, particularly for drugs that may behave differently in diverse patient populations than they do in controlled clinical environments. As a result, pharmaceutical companies and regulators are increasingly incorporating RWE into their pharmacovigilance strategies.

Another key trend is the increased globalization of pharmacovigilance. As pharmaceutical companies expand into international markets, they must comply with the diverse regulatory requirements of different regions. This has led to greater demand for pharmacovigilance services that can operate on a global scale, ensuring that safety data is collected and reported in compliance with local regulations. Regulatory authorities in regions such as the U.S., Europe, and Asia-Pacific have developed stringent guidelines for drug safety, which require pharmaceutical companies to maintain robust pharmacovigilance systems capable of meeting these standards.

Risk management and proactive safety monitoring are also gaining importance in pharmacovigilance. Rather than reacting to adverse events after they occur, companies are increasingly adopting risk management plans (RMPs) and risk mitigation strategies to prevent potential safety issues before they arise. These approaches include pre-market risk assessments, continuous post-market surveillance, and the use of signal detection tools that identify emerging risks from data trends. Additionally, the rise of patient-centric pharmacovigilance emphasizes the importance of direct input from patients, with companies utilizing surveys, social media, and mobile health apps to collect patient-reported outcomes and experiences with medications.

What Is Driving the Growth of the Pharmacovigilance Market?

The growth in the pharmacovigilance market is driven by several factors, including increased regulatory scrutiny, the rising complexity of drug therapies, and technological innovations. One of the primary drivers is the growing number of new drug approvals, particularly in areas such as biologics, gene therapies, and personalized medicines. These therapies are often associated with complex safety profiles, requiring more intensive post-market monitoring. As pharmaceutical companies bring more innovative and personalized drugs to market, the demand for comprehensive pharmacovigilance services to ensure patient safety is expected to rise significantly.

Another important factor driving market growth is the increasing regulatory requirements for drug safety. Regulatory bodies, such as the U.S. FDA and the European Medicines Agency (EMA), have implemented stringent guidelines for pharmacovigilance, requiring companies to conduct ongoing monitoring of drugs even after they receive market approval. Failure to comply with these regulations can result in significant penalties, product recalls, or damage to a company’s reputation. As a result, pharmaceutical companies are investing heavily in pharmacovigilance systems to ensure compliance and avoid regulatory risks.

Technological advancements are also contributing to the growth of the pharmacovigilance market. The integration of AI, automation, and big data analytics has revolutionized the way companies approach drug safety monitoring, making it more efficient, scalable, and cost-effective. These technologies enable companies to analyze vast amounts of data in real-time, improving the speed and accuracy of safety assessments. Furthermore, the rise of cloud-based solutions and global pharmacovigilance networks has facilitated better collaboration and data sharing across the pharmaceutical industry, driving further growth in the market.

Lastly, the increasing focus on patient safety and transparency is a key growth driver. As patients become more informed about the potential risks associated with medications, pharmaceutical companies are under greater pressure to ensure that their drugs are safe and that adverse events are reported quickly and transparently. This shift toward greater accountability and patient-centric approaches is driving the demand for robust pharmacovigilance systems that can monitor drug safety and provide timely updates to regulatory authorities and healthcare providers. These factors, combined with the ongoing development of innovative therapies, are expected to continue driving growth in the pharmacovigilance market in the years to come.

Select Competitors (Total 32 Featured) -

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â